Evidence map›Paper›PMID 19843521›Full record

ArticleThe Journal of biological chemistry2010

IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype.

Guido T Bommer, Ying Feng, Ayaka Iura, Thomas J Giordano, Rork Kuick, Hüseyin Kadikoy, Deanna Sikorski, Rong Wu, Kathleen R Cho, Eric R Fearon

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Aspartate β-hydroxylase as a target for cancer therapy.Journal of experimental & clinical cancer research : CR · 2020
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Guido T BommerDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA.
Ying Feng
Ayaka Iura
Thomas J Giordano
Rork Kuick
Hüseyin Kadikoy
Deanna Sikorski
Rong Wu
Kathleen R Cho
Eric R Fearon
University of Michigan–Ann Arbor · USCancer Genetics (United States) · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Molecular Pathogenesis of Ovarian Endometrioid AdenocarcinomasR01CA094172 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHO, KATHLEEN R. · 2002 to 2011
$2.8M
The Role of Beta-catenin/Tcf Pathway Defects in CancerR01CA085463 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FEARON, ERIC R. · 2000 to 2009
$2.7M
NCI NIH HHS CA046592NCI NIH HHS CA085463NCI NIH HHS CA094172NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA085463NCI NIH HHS R01 CA094172NCI NIH HHS R01CA94172
6 · The paper itself

Abstract

Dysregulation of beta-catenin levels and localization and constitutive activation of beta-catenin/TCF (T cell factor)-regulated gene expression occur in many cancers, including the majority of colorectal carcinomas and a subset of ovarian endometrioid adenocarcinomas. Based on the results of microarray-based gene expression profiling we found the insulin receptor substrate 1 (IRS1) gene as one of the most highly up-regulated genes upon ectopic expression of a mutant, constitutively active form of beta-catenin in the rat kidney epithelial cell line RK3E. We demonstrate expression of IRS1 can be directly activated by beta-catenin, likely in part via beta-catenin/TCF binding to TCF consensus binding elements located in the first intron and downstream of the IRS1 transcriptional start site. Consistent with the proposal that beta-catenin is an important regulator of IRS1 expression in vivo, we observed that IRS1 is highly expressed in many cancers with constitutive stabilization of beta-catenin, such as colorectal carcinomas and ovarian endometrioid adenocarcinomas. Using a short hairpin RNA approach to abrogate IRS1 expression and function, we found that IRS1 function is required for efficient de novo neoplastic transformation by beta-catenin in RK3E cells. Our findings add to the growing body of data implicating IRS1 as a critical signaling component in cancer development and progression.

Indexed as

PhenotypeSignal TransductionAnimalsbeta CateninCell Line, TumorCell Transformation, NeoplasticGene Expression Regulation, NeoplasticHumansInsulin Receptor Substrate ProteinsMiceMutationNeoplasmsOncogenesRatsWnt Proteinsbeta CateninInsulin Receptor Substrate ProteinsIRS1 protein, humanWnt Proteins

Identifiers

PMID19843521
PMCPMC2804351
OpenAlexW2010052382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.